Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium
暂无分享,去创建一个
Marco Valgimigli | Pascal Vranckx | Mitchell W Krucoff | Sanjay Kaul | Eugenia Nikolsky | David Taggart | Deepak L. Bhatt | Roxana Mehran | Deepak L Bhatt | Sunil V. Rao | S. Kaul | H. White | E. Ohman | M. Krucoff | R. Mehran | M. Valgimigli | J. Sabik | C. Gibson | P. Steg | D. Cutlip | P. Vranckx | E. Nikolsky | S. Wiviott | A. Caixeta | J. Eikelboom | V. Menon | V. Serebruany | D. Taggart | Joseph F Sabik | E Magnus Ohman | C Michael Gibson | Donald E Cutlip | Stephen D Wiviott | Sunil V Rao | Harvey White | Philippe Gabriel Steg | Adriano Caixeta | John Eikelboom | Venu Menon | Victor Serebruany | S. Rao | C. Gibson
[1] Sunil V. Rao,et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.
[2] Deepak L. Bhatt,et al. Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial , 2010, Circulation.
[3] S. Pocock,et al. A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.
[4] Rizwan Afzal,et al. Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction , 2010, Journal of Thrombosis and Thrombolysis.
[5] Deepak L. Bhatt,et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis , 2010, European heart journal.
[6] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[7] A. Kastrati,et al. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. , 2010, The American journal of cardiology.
[8] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[9] S. Steinhubl,et al. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. , 2010, American heart journal.
[10] A. Shroyer,et al. On-pump versus off-pump coronary-artery bypass surgery. , 2009, The New England journal of medicine.
[11] Sunil V. Rao,et al. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. , 2009, American heart journal.
[12] M. Pencina,et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. , 2009, JACC. Cardiovascular interventions.
[13] B. Gersh,et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.
[14] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[15] E. Antman,et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial , 2009, The Lancet.
[16] J. Mega,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.
[17] D. Holmes,et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. , 2009, Journal of the American College of Cardiology.
[18] Sunil V. Rao,et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry , 2009, Circulation. Cardiovascular interventions.
[19] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[20] G. Stone,et al. Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial , 2009, Circulation.
[21] S. Yusuf,et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. , 2008, European heart journal.
[22] S. Yusuf,et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. , 2008, American heart journal.
[23] Sunil V. Rao,et al. Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding , 2008, Circulation.
[24] Deepak L. Bhatt,et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. , 2008, American heart journal.
[25] G. Guyatt,et al. Guidelines for anticoagulant use in acute coronary syndromes , 2008, The Lancet.
[26] A. Kastrati,et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.
[27] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[28] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[29] Sunil V. Rao,et al. Bleeding after antithrombotic therapy in patients with acute ischemic heart disease , 2008, Journal of Thrombosis and Thrombolysis.
[30] J. Gore,et al. Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? , 2007, Circulation.
[31] J. Ware,et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. , 2007, JAMA.
[32] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[33] J. Rawn. Blood transfusion in cardiac surgery: a silent epidemic revisited. , 2007, Circulation.
[34] Chris A Rogers,et al. Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery , 2007, Circulation.
[35] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[36] E. Topol,et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. , 2007, The American journal of cardiology.
[37] Thomas W. Wallace,et al. The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes , 2007, Clinical cardiology.
[38] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[39] S. Steinhubl,et al. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. , 2007, American heart journal.
[40] K. Eagle,et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.
[41] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[42] R. Califf,et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. , 2007, European heart journal.
[43] P. Leprince,et al. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. , 2007, European heart journal.
[44] H. White,et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.
[45] P. Mannucci,et al. Drug therapy: Prevention and treatment of major blood loss , 2007 .
[46] P. Kumar,et al. Prevention and treatment of major blood loss. , 2007, The New England journal of medicine.
[47] K. Wernecke,et al. Three-year survival after four major post–cardiac operative complications* , 2006, Critical care medicine.
[48] Deepak L. Bhatt,et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. , 2006, Journal of the American College of Cardiology.
[49] S. Steinhubl,et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.
[50] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[51] Eric Peterson,et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. , 2006, Journal of the American College of Cardiology.
[52] Salim Yusuf,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.
[53] G. Torelli,et al. Pathophysiology of bleeding in surgery. , 2006, Transplantation proceedings.
[54] Robert M Califf,et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.
[55] R. Collins,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[56] R. Califf,et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.
[57] J. van der Linden,et al. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. , 2005, The Annals of thoracic surgery.
[58] J. van der Linden,et al. Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial , 2005, Circulation.
[59] R. Giugliano,et al. Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.
[60] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[61] H. White,et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.
[62] Sunil V. Rao,et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.
[63] E. Topol,et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. , 2004, JAMA.
[64] W Klein,et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.
[65] N. Weissman,et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.
[66] B. Riou,et al. Identification des facteurs prédictifs de transfusion sanguine homologue en chirurgie cardiaque à partir d’une étude observationnelle , 2003 .
[67] M. Niculescu,et al. [Identification of risk factors for allogenic transfusion in cardiac surgery from an observational study]. , 2003, Annales francaises d'anesthesie et de reanimation.
[68] E. Antman,et al. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. , 2002, American heart journal.
[69] Assent investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.
[70] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[71] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[72] C. Cannon,et al. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. , 1995, Circulation.
[73] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[74] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.
[75] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.